<article id="automated_documentation_steps" class="slide automated-documentation-steps" data-ag-name="Automated documentation steps">
  <div class="tab-title">wAMD</div>

  <h2 class="slide-title">EYLEA<sup class="reg">&reg;</sup> DEMONSTRATED <br>VISUAL ACUITY GAINS<sup class="footnote-link">1</sup></h2>
  <div class="chart">
    <div class="chart-desc">
      Proportion of patients who gained ≥15 letters at 1 year (2<sup class="footnote-link">o</sup> endpoint)
    </div>
    <div class="chart-img"><img src="content_EN/img/charts_va-wamd.png" /></div>
    <div class="chart-details">
      <span>Adapted from EYLEA<sup class="reg">&reg;</sup> Product Monograph.</span> <span>Treatment difference: VIEW 1 (-0.4%; 95% CI [-7.7, 7.0]); VIEW 2 (-2.7%, 95% CI [-10.2, 4.9])</span>
    </div>
    <div class="further-details two-lines">
        <p>EYLEA<sup class="reg">&reg;</sup> achieved comparable visual acuity gains vs. ranibizumab at 52&nbsp;weeks with 37% fewer mean injections (7.6 vs. 12.1) in VIEW 1</p>
        <span class="parallelogram"></span>

    </div>
  </div>
  <div class="reveal-study-design"><span>+</span><span>Study Design</span></div>
  <div id="popup-text">
    <h3>STUDY DESIGN</h3>
    <p>
      <span class='bullet'>*</span>VIEW 1 was a randomized, multicentre, double-blind, active-controlled study in adult patients with wAMD. Patients were assigned in a 1:1:1:1 ratio to either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q8 following 3 initial monthly doses (n=303), EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 (n=304), EYLEA<sup class="reg">&reg;</sup> 0.5&nbsp;mg Q4 (n=304) or ranibizumab 0.5&nbsp;mg Q4 (n=306). This trial included doses that differ from the recommended dose of EYLEA<sup class="reg">&reg;</sup>. The recommended dose of EYLEA<sup class="reg">&reg;</sup> is 2&nbsp;mg (0.05&nbsp;mL, or 50&nbsp;µL) administered by intravitreal injection monthly for 3 initial doses followed by one dose administered once every 2 months. 
    </p>
    <p>
      <span class='bullet'>†</span>VIEW 2 was a randomized, multicentre, double-blind, active-controlled study in adult patients with wAMD. Patients were assigned in a 1:1:1:1 ratio to either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q8 following 3 initial monthly doses (n=313),EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 (n=313),EYLEA<sup class="reg">&reg;</sup> 0.5&nbsp;mg Q4 (n=311) or ranibizumab 0.5&nbsp;mg Q4 (n=303). This trial included doses that differ from the recommended dose of EYLEA<sup class="reg">&reg;</sup>. The recommended dose of EYLEA<sup class="reg">&reg;</sup> is 2&nbsp;mg (0.05&nbsp;mL, or 50&nbsp;µL) administered by intravitreal injection monthly for 3 initial doses followed by one dose administered once every 2 months.
    </p>
  </div>
<div id="jump-to-rw"><span class="link">‹‹</span><span>wAMD REAL LIFE SETTING</span></div>
</article>